Naltrexone for treatment of impaired awareness of hypoglycemia in type 1 diabetes: A randomized clinical trial

Journal of Diabetes and Its Complications
Amir MoheetElizabeth R Seaquist

Abstract

Impaired awareness of hypoglycemia (IAH) is a limiting factor in the treatment of type 1 diabetes (T1D) and is a challenging condition to reverse. The objective of this study was to test the hypothesis that naltrexone therapy in subjects with T1D and IAH will improve counterregulatory hormone response and recognition of hypoglycemia symptoms during hypoglycemia. We performed a pilot randomized double blind trial of 4weeks of naltrexone therapy (n=10) or placebo (n=12) given orally in subjects with T1D and IAH. Outcome measures included hypoglycemia symptom scores, counterregulatory hormone levels and thalamic activation as measured by cerebral blood flow using MRI during experimental hypoglycemia in all subjects before and after 4weeks of intervention. After 4weeks of therapy with naltrexone or placebo, no significant differences in response to hypoglycemia were seen in any outcomes of interest within each group. In this small study, short-term treatment with naltrexone did not improve recognition of hypoglycemia symptoms or counterregulatory hormone response during experimental hypoglycemia in subjects with T1D and IAH. Whether this lack of effect is related to the small sample size or due to the dose, the advanced stage of st...Continue Reading

Associated Clinical Trials

References

Apr 5, 2008·Diabetic Medicine : a Journal of the British Diabetic Association·J GeddesB M Frier
Jul 2, 2009·The Journal of Clinical Endocrinology and Metabolism·James LeuIlan Gabriely
Sep 16, 2011·The Journal of Clinical Endocrinology and Metabolism·Septimiu VeleIlan Gabriely
Nov 8, 2011·The Journal of Clinical Endocrinology and Metabolism·Rory J McCrimmon
Aug 16, 2012·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·Silvia MangiaElizabeth R Seaquist

❮ Previous
Next ❯

Citations

Aug 16, 2016·Current Diabetes Reports·Dayna E McGill, Lynne L Levitsky
Nov 17, 2017·Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research·Eric Lontchi-YimagouMeredith Hawkins
Feb 9, 2018·Diabetologia·Alison D McNeilly, Rory J McCrimmon
Jan 29, 2019·Endocrine Reviews·Sarah StanleyElizabeth R Seaquist
Sep 2, 2017·Diabetes·Michelle CareyMeredith Hawkins
Jul 21, 2021·Journal of Diabetes Science and Technology·Evan OlawskyLisa S Chow

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.